Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

GLAND is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 4.680000
forwardPE 25.349024
debtToEquity 2.738000
earningsGrowth 0.964000
revenueGrowth 0.223000
grossMargins 0.619670
operatingMargins 0.232020
trailingEps 62.270000
forwardEps 91.246120

The current ratio for Gland Pharma Limited is 4.68, indicating that the company can service its short-term debt using available cash and assets. This suggests Gland Pharma Limited has strong liquidity, with more than enough resources to meet its immediate financial commitments.
Gland Pharma Limited's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
Positive earnings and revenue growth for GLAND suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
GLAND's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.
GLAND's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that GLAND is likely to outperform its previous year's financial performance.

Price projections:

Price projections for GLAND
Price projections for GLAND

Gland Pharma Limited's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


11 GLAND sales were executed, with market price at 2113.2000066583805.No sell transactions took place in the period under consideration.The recent trend of increased buying at GLAND's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


A recent buy bias from analysts toward GLAND indicates strong confidence in the stock's future performance. This could encourage investors to park their money in GLAND, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.